Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck, Ariad Link For Cancer Drug

July 16, 2007 | A version of this story appeared in Volume 85, Issue 29

Merck & Co. and Ariad Pharmaceuticals will collaborate on the development and commercialization of the Ariad cancer drug AP23573. Under the deal, Merck will pay Ariad $75 million up front and up to $452 million more in milestone payments. AP23573 is a small-molecule inhibitor of the protein mTOR, considered a "master switch" in cancer cells. The drug is expected to enter Phase III trials for the treatment of metastatic sarcomas later this quarter.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.